As expected, low cash burn rate, hence on schedule for trial enlisting and follow up evaluations.
As stated by the company public announcements on several disclosures ptx's science is in 'pregnency mode', that is their drugs on trial are not needing, at current, further developement but rather validation alone.
Funded well to at least phase 2 in all trails, happy to hold and accumilate.
GLTAH
